dry eye disease

Aerie CEO exits days after downplaying midphase eye disease flop
Fierce Biotech
Tue, 09/21/21 - 10:59 am
Aerie CEO
Vicente Anido
TRPM8
dry eye disease
Aerie touts silver linings from failed PhIIb, plots PhIII in dry eye disease
Endpoints
Thu, 09/16/21 - 10:58 am
Aerie Pharmaceuticals
clinical trials
dry eye disease
AR-15512
Oyster Point Pharma Inks Deal with Ji Xing for Dry Eye Disease Therapies
BioSpace
Sun, 08/8/21 - 12:00 am
Oyster Point Pharma
Ji Xing Pharmaceuticals
OC-01
OC-02
dry eye disease
China
AbbVie revives DTC ads for dry eye med Restasis with a patient front and center
Fierce Pharma
Mon, 04/26/21 - 10:48 am
Allergan
Restasis
dry eye disease
DTC advertising
television ads
Two biotechs target dry eye disease after Novartis’ Xiidra problems
Pharmaforum
Thu, 03/4/21 - 09:57 am
dry eye disease
Novartis
Xiidra
Sylentis
Azura Ophthalmics
FDA Accepts NDA for Oyster Point’s Dry Eye Therapy OC-01
BioSpace
Tue, 03/2/21 - 11:56 pm
Oyster Point
OC-01
dry eye disease
FDA
Unmet Need in Dry Eye Disease Market Leaves Room for Other Drugmakers to Step In
BioSpace
Fri, 11/13/20 - 12:49 pm
dry eye disease
Novartis
Allergan
Sun Pharma
Bausch
Kala Pharmaceuticals
A little biotech's second crack at dry eye disease comes up short. And this time there will be no extra shot at success
Endpoints
Mon, 11/2/20 - 11:07 pm
Aurinia Pharmaceuticals
VOS
dry eye disease
clinical trials
Kala Gets the Greenlight from FDA for Dry Eye Disease Treatment
BioSpace
Tue, 10/27/20 - 11:30 pm
Kala Pharmaceuticals
FDA
Eysuvis
dry eye disease
Ocular Therapeutix announces topline phase 1 clinical trial results of OTX-CSI
Pharmaceutical Business Review
Mon, 10/12/20 - 10:38 am
Ocular Therapeutix
dry eye disease
clinical trials
OTX-CS1
Go or no go? Vaccine panel upstages US approval decisions
EP Vantage
Fri, 10/2/20 - 12:44 pm
FDA
vaccines
COVID-19
advisory panel
Eysuvis
Brilinta
Kala Pharmaceuticals
dry eye disease
Regeneron
AstraZeneca
stroke
Novartis introduces inflammatory villain in its first Xiidra dry eye DTC campaign
Fierce Pharma
Thu, 07/23/20 - 10:51 am
Novartis
Xiidra
DTC advertising
dry eye disease
Takeda takes a $200M hit after Novartis is forced to yank its marketing application for Xiidra
Endpoints
Mon, 06/29/20 - 10:26 am
Takeda
Novartis
Xiidra
Europe
EMA
dry eye disease
Novartis strikes out with dry eye med Xiidra in Europe
Seeking Alpha
Fri, 06/26/20 - 09:52 am
Novartis
dry eye disease
Europe
Xiidra
CHMP
Ocular Therapeutix announces first patient dosed in phase 1 clinical trial of OTX-CSI to treat dry eye disease
Pharmaceutical Business Review
Wed, 05/13/20 - 10:50 am
Ocular Therapeutix
dry eye disease
clinical trials
OTX-CSI
Small biotech Oyster Point sets up pitch to disrupt dry eye market with nasal spray
Endpoints
Mon, 05/11/20 - 10:36 am
Oyster Point Pharma
dry eye disease
OC-01
Allergan
Restasis
Shire
Xiidra
With positive key trial, Kala Pharma's dry eye drug Eysuvis emulates approval path set by Xiidra
Endpoints
Mon, 03/9/20 - 10:07 am
Kala Pharma
Eysuvius
dry eye disease
clinical trials
Neuroptika announces enrollment of first patient in phase 2 clinical trial for dry eye disease
Pharmaceutical Business Review
Fri, 01/17/20 - 12:05 pm
Neuroptika
dry eye disease
NRO-1
clinical trials
Aerie Pharmaceuticals agrees to acquire Avizorex Pharma
Pharmaceutical Business Review
Tue, 11/19/19 - 09:59 am
Aerie Pharmaceuticals
Avizorex Pharma
M&A
ophthalmic
dry eye disease
Upcoming events – Axsome takes on migraine and Kala looks to dry eye again
EP Vantage
Sun, 11/10/19 - 07:58 pm
Axsome Therapeutics
migraines
AXS-07
Kala Pharmaceuticals
clinical trials
KP-121
dry eye disease

Pages